Exercise jumpstarts quality of life in lung ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 3
Volume 18
Issue 3

Early-stage lung cancer patients who exercise regularly have a better quality of life, according to a study conducted at Philadelphia’s Fox Chase Cancer Center.

Early-stage lung cancer patients who exercise regularly have a better quality of life, according to a study conducted at Philadelphia’s Fox Chase Cancer Center.

The researchers followed 175 people who completed surgical treatment for early-stage non-small-cell lung cancer within the previous six years (Cancer Epidemiol Biomarkers Prev 18: 664-672, 2009).

Patients were asked to estimate their physical activity level six months prior to their diagnosis and six months post-treatment.

One in four participants met physical activity guidelines-60 minutes each week of strenuous activity or 150 minutes of moderate exercise-and reported a better quality of life.

Recent Videos
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
Related Content